Market Barriers to the Development of Pharmacotherapies for the Treatment of Cocaine Abuse and Addiction: Final Report. References

09/12/1997

21 CFR 291 Drugs Used for Treatment of Narcotic Addicts.

Abt Associates. Rhodes W, Scheiman P, Pittayathikhum T, Collins L, and Tsarfaty V. Synthetic estimation applied to the prevalence of drug use. The Journal of Drug Issues. 1993;23(2): 297 - 321.

Agency for Health Care Policy and Research. Smoking cessation guideline technical report, number 18. National Technical Information Service, 1996. (NTIS No. PB97 - 104699).

Anderman B and Griffith RW. Clozapine-induced agranulocytosis: A situation report up to August 1976. Europ. J. Clin. Pharmacol. 1977;11: 199 - 201.

Behavioral Health Treatment. Naltrexone splits addiction community: awaiting more data, clinicians wonder it it's right to prescribe pills for alcoholism. Behavioral Health Treatment. 1996;1(4): 1-2.

Boodman SG. New hope for schizophrenia? The Washington Post. 16 February 1993; A10.

Bradford, A. President. Generico, Inc. Telephone interview. June 11, 1997.

Bradford, A. Telephone interview. June 17, 1997.

Brandeis University. Drug Services Research Survey: Phase I. Report to the National Institute on Drug Abuse. Waltham, Massachusetts, 1993a.

Brandeis University. Drug Services Research Survey: Final Report, Phase II. Report to the National Institute on Drug Abuse. Waltham, Massachusetts, 1993b.

CDC. Center for Disease Control's Tobacco Information and Prevention Source page. Statistics from the CDC's home page, http:/www.cdc.gov/nccdphp/osh.

Center for Substance Abuse Treatment. (1994) Approval and monitoring of narcotic treatment programs: a guide on the roles of federal and state agencies. Treatment Assistance Publication (TAP) Series #12.

Center for Substance Abuse Treatment. LAAM in the treatment of opiate addiction". Treatment Improvement Protocol (TIP) Series #22, 1995.

Crabtree BL. Review of naltrexone, a long-acting opiate antagonist. Drug Review. 1984; 3: 273 - 280.

Cruzan S. Clozapine approved for schizophrenia. Food and Drug Administration. 1989, Oct. 3. Press Release.

Cummings L. Personal Communications Lee Cummings, J.D., National Institute on Drug Abuse, August 8, 1997.

Demetrios J. NIDA's Naltrexone Research Program. NIDA Research Monograph. 1976;9: 5-11.

Denmead G., Fountain D., Harwood H, and Zhang D. Substance Abuse Treatment Services: Treatment Facilities and Funded Capacity. Report to the Office of Applied Studies, SAMHSA. Lewin-VHI, Inc., Fairfax, VA September, 1995.

Eissenberg, T. et al. Dose-related efficacy of levomethadyl acetate for treatment of opioid dependence: a randomized clinical trial. Journal of American Medical Association. 1997;277(24): 1945 - 1951.

Ereshefsky L, Wantanabe MD, Tran-Johnson TK. Drug review: clozapine: an atypical antipsychotic agent. Clinical Pharmacy. 1989;8: 691 - 709.

Everingham SC, and Rydell CP. (1994). Modeling the Demand for Cocaine. Drug Policy Research Center. RAND Corporation.

Feldman R., Fountain D, and Carney B. Demand for and Barriers to Use of LAAM: A Case Study of the Implementation of New Pharmacotherapies in the Treatment of Opiate Addiction. Report prepared for the Office of Science Policy, Legislation, and Education at NIDA, 1994.

Garrett HM. Ed. Red Book. Montvale, N.J., Medical Economics Data Production, 1994.

Gauen SE and Lee NL. Pharmacists' role in a smoking-cessation program at a managed health care organization. American Journal of Health Systems Pharmacology. 1995;52 (3): 294-6.

Geifler, R. President. Orpharm, Inc. Telephone interview. June 17, 1997.

Gerstein D. et al. Evaluating Recovery Services: The California Drug and Alcohol Treatment Assessment (CALDATA). Report to the State of California, Department of Alcohol and Drug Programs, Sacramento, CA, 1994.

Gerstein, D., and H. Harwood. eds. Treating Drug Problems. Volume 1: A Study of the Evolution, Effectiveness, and Financing of Public and Private drug treatment Systems, National Academy Press, 1990.

Hamill D. and Cooley P. National Estimates of Heroin Prevalence 1980-1987: Results from Analysis of DAWN Emergency Room Data. RTI Technical Report. Triangle Park, N.J.: Research Triangle Institute, 1990.

Harwood H, Thomson M, and Nesmith T. Healthcare Reform and Substance Abuse Treatment: The Cost of Financing Under Alternative Approaches. Fairfax, VA: Lewin-VHI, 1994.

Harwood, H., et al. How Many People are in Need of Treatment. Submitted to CSR, Inc. and the Office of National Drug Control Policy by Lewin-VHI, Inc. Fairfax, VA: Lewin-VHI, 1993.

Harwood H., Thomson M., Nesmith T. Healthcare Reform And Substance Abuse Treatment: The Cost of Financing Under Alternative Approaches. A Report to the Legal Action Center. Fairfax, VA: Lewin-VHI, Inc., February 1984.

Harwood HJ., et al. Economic Costs to Society of Alcohol and Drug Abuse and Mental Illness: 1980, submitted to the Alcohol, Drug Abuse, and Mental Health Administration, June 1984.

Haxby DG. Treatment of nicotine dependence. American Journal of Health Systems Pharmacology. 1995;52(3): 265-81.

Hebert JR, Kristeller J, Ockene JK, Landon J, Luippold R, Goldberg RJ, Kalan K. Patient characteristics and the effect of three physician-delivered smoking interventions. Preventive Medicine. 1992;21(5): 557-73.

Henry JA, Rivas CA. Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Pharmacoeconomics. 1997;11(5): 419-443.

Hirschfeld RMA, Keller MB, Panico S, Arons BS, Barlow D, Davidoff F, et. al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA; 1997;277(4): 333-340.

Homer JB.. A system dynamics model for cocaine prevalence estimation and trend projection. The Journal of Drug Issues. 1992;23(2): 251-279.

Hospital and Community Psychiatry. Sandoz guidelines for clozapine monitoring called too restrictive. Hospital and Community Psychiatry. 1991;42(5): 545.

IMS, Antidepressant Market Dollars by Channel, 1996.

Institute of Medicine. Fulco CE, Liverman CT, and Early LE. Development of medications for the treatment of opiate and cocaine addictions: issues for the government and the private sector. Committee to Study Medication Development and Research at the National Institute on Drug Abuse. Washington, D.C.: National Academy Press, 1995.

Institute of Medicine. Treating Drug Problems. Vol. I. Gerstein DR and Harwood HJ (Eds.). Committee for the Substance Abuse Coverage Study, Division of Health Care Services. Washington, D.C.: National Academy Press, 1990a.

Irvin SM. Treatment of depression with outpatient electroconvulsive therapy. AORN Journal. 1997; 65(3): 573-582.

Jaffe JH, Schuster CR, Smith BB, and Blachly PH. Comparison of acetylmethadol and methadone in the treatment of long-term heroin users: A pilot study. Journal of the American Medical Association. 1970;211: 1834-1836.

Johnson R, Gerstein D, Ghadialy R, and Gfroer J. Trends in the Incidence of Drug Use in the United States, 1919-1992. DHHS Publication No. (SMA) 96-3076, SAMHSA, Rockville, MD, 1996.

Johnston L. et al. National Survey Results on Drug Use from the Monitoring the Future Study, 1975 - 1993. National Institute on Drug Abuse (NIDA), Volume II, 1994.

Julius D. NIDA's Naltrexone Research Program. Nida Research Monograph. 1976;9: 5 - 11.

Kaim SC. Evolution of the National Academy of Sciences Study of Naltrexone. NIDA Research Monograph. 1976;9: 37-44.

Kunze RJ. Nothing Ventured: The Perils and Payoffs of the Great American Venture Capital Game. New York, NY: HarperBusiness: 1993.

Law M and Tang JL. An analysis of the effectiveness of interventions intended to help people stop smoking. Archives of Internal Medicine. 1995; 155 (18): 1933-41.

Lazowick AL. Managing patients with depression. Drug Topics Supplement. 1997; 40s-43s.

Martin WR, Jasinski DR, Mansky PA. Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man. Arch Gen Psychiatry. 1977; 28: 784 - 91.

Martin WR and Jasinski DR. Characterization of EN-1639A. Clinical Pharmacol Ther. 1973;14: 142.

Medications Development Division. "Information on LAAM." Report prepared by the National Institute on Drug Abuse on the history of LAAM, 1994.

National Association of State Alcohol and Drug Abuse Directors (NASADAD) (Annual). State Resources and Services Related to Alcohol and Other Drug Problems. A Report to the Office of Applied Studies, Substance Abuse and Mental Health Services Administration, Rockville, MD.

Niaura R; Goldstein MG; Abrams DB. Matching high- and low-dependence smokers to self-help treatment with or without nicotine replacement. Preventive Medicine. 1994; 23 (1): 70-7.

Nunn-Thompson CL and Simon PA. Pharmacotherapy for smoking cessation. Clinical Pharmacology. 1989;8 (10): 710-20.

O'Brien CP, Greenstein R, Ternes J, Woody GE. Clinical pharmacology of narcotic antagonists. Annals of the NY Acad of Sciences. 1978;311: 232 - 240.

O'Brien CP, Volpicelli LA, Vopicelli JR. Naltrexone in the treatment of alcoholism: a clinical review. Alcohol. 1996;13 (1): 35 - 39.

O'Malley SS. Current strategies for the treatment of alcohol dependence in the United States. Drug and Alcohol Dependence. 1995;39 (Suppl. 1): S3 - S7.

Office of Applied Studies. Overview of the FY94 National Drug and Alcoholism Treatment Unit Survey (NDATUS) Data from 1993 and 1980-1993. Advance Report Number 9A. SAMHSA, Rockville, MD August, 1995.

Office of Applied Studies. National Drug and Alcoholism Treatment Unit Survey (NDATUS) Data for 1994 and 1980-1994. Advance Report Number 13. SAMHSA, Rockville, MD June, 1996.

Office of Applied Studies. National Household Survey on Drug Abuse: Population Estimates 1995. Substance Abuse and Mental Health Services Administration. US Department of Health and Human Services. Public Health Service, 1996.

Office of Applied Studies. Correspondence from Joan Epstein. Substance Abuse and Mental Health Services Administration. US Department of Health and Human Services. Public Health Service, 1997.

Office of Applied Studies. National Drug and Alcoholism Treatment Unit Survey (NDATUS) 191 Main Findings Report. DHHS Publication No. (SMA) 93-2007 SAMHSA, Rockville, MD, 1997.

Office of Applied Studies. National Admissions to Substance Abuse Treatment Services: The Treatment Episode Data Set (TEDS) 1992-1995. Advance Report Number 12, Treatment Episode Data Set. SAMHSA, Rockville, MD, February, 1997.

O'Malley SS. Strategies to maximize the efficacy of Naltrexone for alcohol dependence. NIDA Res Monogr. 1995;150: 53-64.

Oncology. Cancer pain remedy wins orphan drug status. Oncology. 1996;10(12): 1880.

Peck CC. FDA's position on the clozaril patient management system. Hospital and Community Psychiatry. 1990;41 (8): 876 - 877.

Pharmaceutical Approvals Monthly. New Drug Reviews: Abbott Serlect Schizophrenia Seven-Arm Study Could Meet FDA Standards for Comparative Labeling; Serlect will Compete Against Lilly's Zyprexa. Pharmaceutical Approvals Monthly. 1996;1(11).

Pink Sheet. 1994, September 5: 56 (36).

Pink Sheet. 1995, January 9: 57 (2).

Pink Sheet. 1996, March 18: 58 (12).

Pink Sheet. Clozaril active patient population has increased to 15,000, doubling since end of 1990. The Pink Sheet. 1991, Oct. 28: 53(43).

Pink Sheet. Marion Merrell Dow Cardizem line sales up 15% to $1.1. billion in 1992; Nicoderm contribute $27 million. The Pink Sheet. April 22, 1996, 4 (17).

Pink Sheet. Nicotine gum over-the-counter: only 12.4% of managed care plans would cover the product according to CHPG study. The Pink Sheet, October 9, 1995, 57(41).

Pink Sheet. SmithKline Beecham, Marion Merrell Dow combined OTC business has baseline sales of $660 million; venture provides critical mass, launching pad for switches. The Pink Sheet. August 24, 1992, 54 (34).

Plank SJ. Worksite smoking cessation using nicotine resin gum (Nicorette). American Journal of Public Health. 1987;77 (8): 1013-4.

Rawson, R. et al. (1996) A Three Year Progress Report on the Implementation of LAAM. Report written by researchers from the Friends Medical Science Research Center, Matrix Institute on Addictions, and the West Los Angeles VA Medications Development Research Unit.

Rawson, R. Friends Medical Science Research Center. Telephone interview. May 20, 1997.

Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ and Goodwin FK. The de facto US mental and addictive disorder service system. Archives of General Psychiatry 1993;50.

Report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Arch Gen Psychiatry. 1978; 35: 335 - 40.

Resnick RB, Volavka J, Freeman AM et al. Studies of EN-1639A (naltrexone): a new narcotic antagonist. Am J Psychiatry. 1974; 131: 646 - 50.

Rhodes, W. Synthetic estimation applied to the prevalence of drug use. The Journal of Drug Issues. 1993;23(2), 297-321.

Rhodes W, Scheiman P, Pittayathikhum T, Collins L, and Tsarfaty V. What America's Users Spend on Illegal Drugs, 1988-1993. Executive Office of the President. Office of National Drug Control Policy, 1995.

Rice DP et al. The Economic Costs of Alcohol and Drug Abuse and Mental Illness: 1985, Report submitted to the Office of Financing and Coverage Policy of the Alcohol, Drug Abuse and Mental Health Administration, US Department of Health and Human Services, San Francisco, CA: Institute for Health and Aging, University of California, 1990.

Richards JW Jr . Cigarette smoking and Nicorette gum". Annals of Internal Medicine. 1987;106 (3): 482-3.

Sachs DP and Leischow SJ. Pharmacologic approaches to smoking cessation. Clinical Chest Medicine. 1991;12 (4): 769-91.

Schecter AJ, Friedman JG, Grossman DJ. Clinical use of naltrexone (EN-1639A): Part I: safety and efficacy in pilot studies. American Journal of Drug and Alcohol Abuse. 1974;1(2): 253 - 269.

Schecter AJ. The role of narcotic antagonists in the rehabilitation of opiate addicts: a review of naltrexone. American Journal of Drug and Alcohol Abuse. 1980;7(1): 1-18.

Scott-Levin, Source Prescription Audit 1996.

Scrip. Clozaril reaching 11,000 US patients and 48 states. Scrip. 1991, June 5: 1622: 14.

Scrip. Naltrexone approved for alcoholism. 1995, January 24: 23.

Scrip. Sandoz Pharma Sandimmun sales in 1993. Scrip. 1994, May 17: 1923: 17.

Sincich J. Director of Marketing. Roxane Laboratories, Inc. Telephone interview. June 27, 1997.

SmithKline Beecham. Nicorette Nicotine Gum to Quit Smoking, now Over the Counter. Information obtained from the Nicorette webpage created in 1997, http://www.nicorette.com.

Spangler JG; Salisbury PL. Smokeless tobacco: epidemiology, health effects and cessation strategies." American Family Physician. 1995;52 (5): 1421-30, 1433-4.

Suchinsky R. Associate Chief of Addicted Disorders, Department of Veteran's Affairs. Telephone interview. July 8, 1997.

Tan Sheet. In brief: Smoking cessation product sales. The Tan Sheet. November 18, 1996, 4 (47).

Tan Sheet. Nicorette 2 mg and 4 mg cleared for OTC use by FDA advisory committee. The Tan Sheet. October 2, 1995, 3 (40).

Tan Sheet. Nicorette actual-use studies support Waxman/Hatch exclusivity, SmithKline counsel argues. The Tan Sheet. April 15, 1996, 4 (16).

Tan Sheet. Nicorette labeling contraindicates use of nicotine patches. The Tan Sheet. February 19, 1996, 4(8).

Tan Sheet. Nicorette OTC use studies meet Waxman/Hatch exclusivity requirements, FDA says. The Tan Sheet. November 11, 1996, 4 (46).

Tan Sheet. Nicorette TV ads begin April 19, featuring "portraits" of quitter." The Tan Sheet. April 22, 1996, 4 (17).

Tan Sheet. OTC Nicorette will be available in retail stores by late spring following February 9 approval. The Tan Sheet. February 12, 1996, 4 (7).

Tan Sheet. OTC switch marketing exclusivity may be facilitated by 'paper trail'. The Tan Sheet. May 20, 1996, 4 (21).

Tan Sheet. Pharmacia & Upjohn Consumer Health sales down 17.8% to $153.2 million in first quarter. The Tan Sheet. May 5, 1997, 5 (18).

Tan Sheet. Pharmacia & Upjohn second quarter consumer health sales up 77% due to Nicorette and Rogaine. The Tan Sheet. August 12, 1996, 4 (33).

Tan Sheet. SmithKline Beecham Consumer takes over Nicorette marketing effective January 1. The Tan Sheet. August 23, 1993, 1 (26).

Tan Sheet. SmithKline Beecham worldwide OTC sales grow 11% to $1.03 billion in 1994, led by Tums. The Tan Sheet. February 27, 1995, 3 (9).

Tan Sheet. SmithKline Beecham's Nicorette/Nicoderm CQ generate $345 million in sales in 1996. The Tan Sheet. February 24, 1997, 5(8).

Tan Sheet. SmithKline forms partnership with American Lung Association to support Nicorette launch. The Tan Sheet. April 22, 1996, 4 (17).

Tan Sheet. SmithKline Nicorette education efforts include web site, Committed Quitters program. The Tan Sheet. April 22, 1996, 4 (17).

Tan Sheet. SmithKline Phase IV commitments include Nicorette study on use by adolescents. The Tan Sheet. February 19, 1996, 4 (8).

Tan Sheet. SmithKline worldwide OTC sales up 18% to $536 million in first quarter. The Tan Sheet. April 28, 1997, 5 (17).

Tan Sheet. Smoking cessation products' broader efficacy claims to be discussed by FDA advisory committee. The Tan Sheet. April 21, 1997, 5 (16).

Tokarski C. VA drops contract with drug maker. Modern Healthcare. 1990;July 30: 26.

United States Department of Health and Human Services. Smoking Deterrent Drug Products for Over-the-Counter Human Use; Establishment of a Monograph. Federal Register. 1982;47(2): 490-500.

US Congress. Senate. Committee on the Judiciary. Hard-Core Cocaine Addicts: Measuring-and Fighting-The Epidemic. A Staff Report Prepared for the Use of the Committee on the Judiciary, 1990.

Vocci F, Cummings L, and Montgomery A. Medications development division, National Institute of Drug Abuse. Interview. May 20, 1997.

Volpicelli JR, Volpicelli LA, O'Brien CP. Medical management of alcohol dependence: clinical use and limitations of naltrexone treatment. Alcohol & Alcoholism. 1996;30(6): 789 - 798.

Warner LA, Kessler RC, Hughes M, Anthony JC, and Nelson CB. Prevalence and correlates of drug use and dependence in the United States: results from the national comorbidity survey. Archives of General Psychiatry, 1995;52: 219-229.

Watson SJ, Akil H, Berger PA, Barchas JD. Some observations on the opiate peptides and schizophrenia. Arch Gen Psychiatry. 1979;36 (1).

Woodward A, Epstein J, Gfroerer J, Melnick D, Thoreson R, and Wilson D. (in Press). The Drug Abuse Treatment Gap: Recent Estimates. Office of Applied Studies, Substance Abuse and Mental Health Services Administration. U.S. Department of Health and Human Services.

Wright C. Personal Communications, Wright C, M.D., Food and Drug Administration, July 16, July 18, 1997.

Wright D, Gfroerer J, and Epstein J. The Use of External Data Sources and Ratio Estimation to Improve Estimates of Hardcore Drug Use from the NHSDA. Presentation at the Annual Meeting of the American Statistical Association, 1994.